

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>A61L 9/04</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/00107</b>  <b>(43) International Publication Date:</b> 9 January 1992 (09.01.92)
<b>(21) International Application Number:</b> PCT/US91/04715 <b>(22) International Filing Date:</b> 27 June 1991 (27.06.91)  <b>(30) Priority data:</b> 545,437 28 June 1990 (28.06.90) US 649,405 1 February 1991 (01.02.91) US  <b>(71) Applicant (for all designated States except US):</b> GLAXO INC. [US/US]; Five Moore Drive, Research Triangle Park, NC 27709 (US).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only) :</b> JOHNSON, Keith, A. [US/US]; 4011 Blakeford Drive, Durham, NC 27707 (US).  <b>(74) Agent:</b> JOYNER, Charles, T.; Glaxo Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US).		<b>(81) Designated States:</b> AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> AEROSOL DRUG FORMULATIONS  <b>(57) Abstract</b>  Aerosol formulations comprising an inhalation drug, 1,1,1,2-tetrafluoroethane (P134a) and a surface active agent soluble in 1,1,1,2-tetrafluoroethane.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

## AEROSOL DRUG FORMULATIONS

Drugs for treating respiratory and nasal disorders are frequently administered in aerosol formulations through the mouth or nose. Peter Byron, Respiratory Drug Delivery, CRC Press, Boca Raton, FL 1990, provides a background for this form of therapy. (As used hereinafter the terms "aerosol drug formulation" and "inhalation drug formulation" are synonymous and refer to one or more physiologically active chemical compounds in combination with excipients such as surface-active agents, "surfactants" and propellants.)

One widely used method for dispensing such an aerosol drug formulation involves making a suspension formulation of the drug as a finely divided powder in a liquefied gas known as a propellant. The suspension is stored in a sealed container capable of withstanding the pressure required to maintain the propellant as a liquid. The suspension is dispensed by activation of a dose metering valve affixed to the container. A metering valve may be designed to consistently release a fixed, predetermined amount of the drug formulation upon each activation. As the suspension is forced from the container through the dose metering valve by the high vapor pressure of the propellant, the propellant rapidly vaporizes leaving a fast moving cloud of very fine particles of the drug formulation. This cloud is usually directed into the body of the patient by a channeling device, e.g., a cylinder like or cone like passage, with one of its ends attached to the outlet of the pressurized container, and the other end inserted in the mouth or nose of the patient. Concurrently with the activation of the aerosol dose metering valve, the patient inhales the drug formulation particles into the lungs or nasal cavity. Systems for dispensing drugs in this way are known as "metered dose inhalers (MDI's)." [Ibid Byron, Pages 167-207.]

Many materials, including drug formulations, have a tendency to aggregate (also referred to as "flocculate" or "clump-up") when stored as fine particles having dimensions of a few microns in a suspension. For an aerosol delivery system to work properly the particle size should generally not exceed about five microns. As

the particle size exceeds five microns, it becomes increasingly difficult to maintain an efficacious aerosol dose with a predictable dispersion pattern upon activation of the metering valve. Further, the suspension should be uniform, that is, substantially free from large aggregates of the drug particle and be substantially homogenous throughout the container.

To minimize or prevent the problem of aggregation of fine particles, compounds known as surface active agents, or surfactants, are used to coat the surfaces of the fine particles and assist in wetting the particles with an aerosol propellant. The use of surfactants in this way to maintain substantially uniform suspensions is said to "stabilize" the suspensions. An ideal surfactant should have a relative high affinity for the suspended drug formulation and be chemically and physically compatible with the propellant as well as the drug formulation. If it does not have these properties, the surfactant can possibly destabilize the suspension. Additionally, it must be essentially nontoxic.

For several years the chlorofluorocarbons (CFC's), for example, trichloromonofluoromethane, dichlorotetrafluoroethane and dichlorodifluoromethane, also known as "propellant 11" or "P 11", "propellant 114" or "P 114" and "propellant 12" or "P 12", respectively, have gained widespread acceptance as the propellants of choice for inhalation drug formulations. They are nonflammable, have low toxicity and reactivity, are compatible with many drug formulations and have the requisite physical attributes. See John Sciarra and Anthony Cutie, *Theory and Practice of Industrial Pharmacy*, Pages 589-619, Lea and Febiger, Philadelphia, 1986. However, in the past few years CFC's have been shown to cause depletion of the ozone layer of the atmosphere, a serious environmental problem. Scientists and governmental officials around the world have called for a phase-out of the use of CFC's. Some countries, e.g., Sweden, have completely banned the use of CFC's for aerosol products, while other counties have levied substantial taxes on them to encourage the use of other, environmentally safer propellants. See Dalby, et al., *Pharmaceutical Technology*, 26, March 1990.

In recent years a nonchlorinated propellant chemically identified as 1,1,1,2-tetrafluoroethane also known as "propellant 134a" or "P 134a" has been promoted by

major chemical manufacturers, notably DuPont and ICI, as an environmentally acceptable alternative to CFC propellants. Propellant 134a has physical properties comparable with P 12. Although like P 12 it is nonflammable and has a relatively low potential for interaction with a wide variety of products normally sold in aerosol form, its other chemical and solvent properties are different from P 12. For example P 134a is much less stable chemically than P 12 according to Dalby, et al. (see above).

Thiel in U.S. patent number 4,357,789 teaches the use of propellant insoluble perfluorinated surface-active dispersing agents in CFC and perfluorinated propellants although P 134a is not specifically mentioned. These agents include perfluorinated sulfonamide alcohol phosphate esters and their salts, perfluorinated alkyl sulfonamide alkylene quaternary ammonium salts and perfluorinated alcohol phosphate esters and their salts. Thiel teaches that surfactants must be insoluble in the propellant. Further, he teaches that the drug must be coated with the surfactant in an organic solvent dried, then added to the propellant mixture.

European Patent Application Publication No. 0 372 777 describes medicinal aerosol formulations which employ P134a as a propellant EPA 0 372 777 teaches that a four component system, comprising drug, surfactant, P134a and an adjuvant having higher polarity than P134a, is essential to obtain medicinal aerosol formulations having suitable properties for use with pressurised inhalers.

It has now been found that P 134a-soluble surfactants, especially soluble perfluorinated surfactants, effectively improve the stability of micronized inhalation drug suspensions in P 134a. (As used herein the terms "perfluorinated" and "perfluoro" mean that for at least one alkyl group essentially all of the hydrogens are substituted with fluorine.) Accordingly, when a micronized drug, i.e., a drug having an average particle size of about 5 microns or below and a maximum particle size of less than about 10 microns, and a P 134a soluble surfactant are placed in P 134a in a pressurized container, there is considerably less tendency for the drug particles to aggregate and separate from the suspension than the drug formulation without such surfactant or with a P 134a hydrocarbon surfactant commonly used with a CFC propellant. Thus it is now possible with the present invention to prepare aerosol

formulations of inhalation drugs with P 134a which have sufficient stability for the purposes of this invention to deliver the active drug in the desired way as presently marketed MDI's, but without the environmental problems associated with CFC's. As used herein the term "sufficient stability" means that the aerosol drug formulation remains as a suspension after shaking at least long enough to allow activation of the MDI and administration by the patient. The time between shaking and administration is typically about 10 sec. and generally for the formulations of this invention the period of stability is at least about 30 sec.

An aspect of this invention is the use of one or more P 134a soluble surfactants to stabilize an inhalation drug in P 134a. A second aspect is an aerosol inhalation drug formulation comprising a physiologically effective amount of a micronized inhalation drug and one or more P 134a soluble surfactants in suspension in P 134a.

In a preferred aspect the invention provides an aerosol drug formulation comprising a physiologically effective amount of micronized inhalation drug and one or more P134a soluble surfactants in suspension in P134a which formulation is substantially free of P134a insoluble surfactant.

In a further or alternative aspect the invention provides an aerosol drug formulation comprising a particulate drug and one or more P134a soluble surfactants in suspension in P134a, which formulation is substantially free of drug which has been coated with surfactant prior to addition to the propellant mixture.

In a further or alternative aspect there is also provided an aerosol drug formulation comprising a medicament, P134a and one or more P134a soluble surfactants which formulation is substantially free of an adjuvant having a higher polarity than P134a. It will be appreciated by those skilled in the art that such a formulation, which is essentially a three component formulation may also contain other excipients normally included in medicinal aerosol formulations.

Especially useful drugs include respiratory drugs such as  $\beta_2$ -stimulants ( $\beta_2$ -agonists), anticholinergic drugs, corticosteroids and antiallergic drugs.

$\beta_2$ -stimulants include for example fenoterol, pirbuterol, reproterol, imiterol, terbutalline, tulobuterol, isoprenaline and oxaprenaline.

Anticholinergic drugs include ipratropium bromide and oxitropium bromide. Corticosteroids include budesonide.

Antiallergic drugs include sodium cromoglycate, ketotifen and nedocromil sodium.

Of particular use in this invention are the respiratory drugs albuterol, salmeterol, amiloride, fluticasone propionate, beclomethasone dipropionate and (-)-4-amino-3,5-dichloro- $\alpha$ -[[[6-(2-pyridinyl)ethoxy]hexyl]amino]methyl]-benzenemethanol.

United States Patent number 3,644,353, incorporated herein by reference, teaches a group of bronchodilating compounds that are particularly useful in the treatment of asthma and other respiratory diseases. The preferred compound taught therein is  $\alpha^1$ -tert-butylaminomethyl-4-hydroxy-m-xylene- $\alpha^1$ ,  $\alpha^3$ -diol, also known in the United States by its generic name, "albuterol" and, in most other countries, "salbutamol." This compound, especially in aerosol form, has been widely accepted by the medical community in the treatment of asthma.

Salmeterol, chemically named 4-hydroxy- $\alpha'$ -[[[6[(4-phenylbutyl)-oxy]hexyl]amino]methyl]-1,3-benzenedimethanol, disclosed in British Patent Application No. 8,310,477, is a second generation bronchodilator which is longer acting and more potent than albuterol. This compound is not yet marketed in the United States, but clinical trials in other countries indicate that a preferred mode of administration is by way of aerosol inhalation.

The genetic disease cystic fibrosis is characterized by abnormalities that produce excessive pulmonary secretion which can make breathing difficult. United States Patent Number 4,501,729, incorporated herein by reference, discloses the use of the drug amiloride in an aerosol formulation to reduce the excess secretion.

United Kingdom Patent Specification No. 2088877 discloses fluticasone esters. Fluticasone esters are corticosteroids having topical anti-inflammatory action. Corticosteroids may be used in the management of patients whose asthma is inadequately treated by bronchodilators and/or sodium cromoglycate.



A further class of corticosteroids having topical anti-inflammatory action, beclomethasone esters, are described in United Kingdom Patent Specification No. 1 047 519.

(-)-4-Amino-3,5-dichloro- $\alpha$ -[[[6-[2-(2-pyridinyl)ethoxy]hexyl]amino]methyl]benzenemethanol is a bronchodilator.

Where appropriate the drugs may be used in the form of salts (e.g. as alkali metal or amine salts or as acid addition salts) or as esters (e.g. as lower alkyl esters).

For use in the invention, albuterol will preferably be in the form of the sulphate salt or the free base and salmeterol will preferably be in the form of its 1-hydroxy-2-naphthoate salt. The preferred fluticasone ester for use in the invention is fluticasone propionate, and the preferred beclomethasone ester is beclomethasone dipropionate.

In addition to surfactants it may be desirable to add other excipients to an aerosol formulation to improve drug delivery, shelf life and patient acceptance. Such optional excipients include, but are not limited to, coloring agents, taste masking agents, buffers, antioxidants and chemical stabilizers.

Inhalation drugs, or a pharmaceutically acceptable salt hereof, may be micronized by, for example, conventional jet mill micronizing to particles ranging from about 0.1 to about 10.0 microns and preferably from about 0.5 to about 5.0 microns. The micronized inhalation drug or combination of drugs are mixed with one or more P 134a-soluble surfactants and, optionally, other excipients and then placed in a suitable container capable of withstanding the vapor pressure of P 134a and fitted with a metering valve. The propellant is then forced as a liquid through the valve into the container. The completed MDI is shaken vigorously to form the suspension.

Alternatively, an MDI can also be produced by adding drug, surfactant and liquefied propellant 134a (chilled below its boiling point) to the container and then a metering valve fitted to the container. The completed MDI can then be brought to ambient temperature and shaken vigorously to form the suspension.

MDI's prepared according to the teachings herein may be used in the same way as currently marketed MDI's which use CFC's or hydrocarbon propellants. For



example, in the case of albuterol, amount of drug, surfactant and propellant can be adjusted to deliver 90  $\mu$ g per valve actuation, the dose delivered in currently marketed albuterol MDI's.

Particular 134a-soluble surfactants include perfluorinated surfactants, especially perfluoroalkanoic acid surfactants having greater than 4 but 20 or less carbons, preferably from 8 to 10 carbons. Also particularly suitable are a mixture of potassium perfluoroalkyl sulfonates and a mixture of ammonium perfluoroalkyl carboxylates available under the trademarks FC-95 and FC-143, respectively, from 3M Corporation, Saint Paul, Minn. Most suitable are the perfluoroalkanoic acids, perfluorooctanoic acid and perfluorodecanoic acid.

The ratio of surfactant to drug is from about 1:100 to about 1:0.5 by weight, preferably in the range of about 1:50 to about 1:1 and most preferably in the range of about 1:25 to about 1:1 by weight. The amount of P 134a can be varied according to the amount of drug formulation to be delivered with each activation of the dose metering valve. Typically for an inhalation drug the amount of P 134a for each formulation of active drug depends on the volume of the metering valve and the dose desired. However the ratio of active drug or drugs to P 134a is in the range from about 1:100 to about 1:4000 by weight. For example, for albuterol in an aerosol inhalation system outfitted with a Bepak BK300 valve, 18 g of P 134a are utilized per 50 mg of albuterol to deliver an effective dose of albuterol.

The instant invention thus provides an aerosol inhalation drug formulation comprising a physiologically effective amount of a micronized drug suitable for inhalation therapy and a propellant 134a-soluble surfactant in suspension in propellant 134a and optionally other excipients.

The following examples are presented for illustration of the invention and are not to be construed as a limitation thereto.

## EXAMPLES

### General Procedure

Micronized drug and surfactant (if used) are weighed into a 15 mL transparent aerosol vial (No. S-24F6, produced by Wheaton Industries, NJ). A metering valve (Bespak valve No. BK300 produced by Bespak plc, England) is crimped onto each vial. Finally, Propellant 134a (from E. I. DuPont de Nemours and Company, Wilmington Del.) is added to the vial through the valve. Vials are then vigorously shaken for 30 min with a wrist-action shaker.

Immediately after shaking, the suspension in the transparent vial is very milky or turbid. If left undisturbed, the drug particles eventually flocculate and concentrate at the gas/liquid interface (creaming) or at the bottom of the vial (settling) leaving behind a relatively clear Propellant 134a region. By shaking a formulation that has separated, it quickly re-disperses to a milky suspension. Suspension stability is assessed by monitoring the rate at which the drug particles flocculates as evidenced by the time required for the suspension to become coarse and/or to develop a relatively clear propellant region. If significant flocculation occurs, that is, a cognizable coarseness and/or clear region can be observed, in less than about 15 sec., the suspension is deemed not stable enough for a practical aerosol inhalation drug formulation.

Alternatively, several suspensions can be shaken simultaneously and the most stable suspension designated as the last one to separate. A suspension of drug in Propellant 134a with no surfactant is used as a control and reference for measuring the stability of the formulations.

The drug and propellant weight ratio is selected based on reasonable ranges of marketed products. The ratio of surfactant weight to drug weight is varied by keeping the drug weight constant and increasing the surfactant weight.

Using the procedure described above, the following data shown on Table 1 below was obtained:

TABLE 1

	<u>Drug (amount)</u>	<u>Surfactant (amount)</u>	<u>Approximate Time Before Significant Flocculation Observed (sec)</u>
Control 1	albuterol (50 mg)	none	<2
Control 2	albuterol (50 mg)	oleic acid (10 mg)	<2
Control 3	albuterol (50 mg)	perfluorobutyric acid (10 mg)	<2
Example 1	albuterol (50 mg)	perfluorooctanoic acid (5 mg)	30
Example 2	albuterol (50 mg)	perfluorooctanoic acid (25 mg)	30
Example 3	albuterol (50 mg)	perfluorooctanoic acid (50 mg)	30
Example 4	albuterol (50 mg)	perfluorodecanoic acid (5 mg)	30
Example 5	albuterol (50 mg)	perfluorodecanoic acid (25 mg)	30
Example 6	albuterol (50 mg)	FC-143 <sup>1</sup> (5 mg)	30
Example 7	albuterol (50 mg)	FC-143 (50 mg)	30
Example 8	albuterol (50 mg)	FC-95 <sup>2</sup> (5 mg)	30
Example 9	albuterol (50 mg)	FC-95 (50 mg)	30
Example 10	salmeterol (20 mg)	perfluorodecanoic acid (5 mg)	180
Example 11	salmeterol (20 mg)	perfluorodecanoic acid (50 mg)	180
Example 12	salmeterol (10 mg)	perfluorodecanoic acid (0.5 mg)	240
Example 13	salmeterol (10 mg)	perfluorodecanoic acid (0.1 mg)	80
Example 14	salmeterol (10 mg)	FC-143 (1 mg)	25
Example 15	salmeterol (10 mg)	FC-95 (1 mg)	40

Example 16	amiloride HCl (100 mg)	perfluorodecanoic acid (20 mg)	150
Example 17	amiloride HCl (100 mg)	perfluorodecanoic acid (70 mg)	150

Propellant 134a weight is 18 g in each control and example.

1. Trademark of 3M Co. for a mixture of ammonium perfluoroalkyl carboxylates
2. Trademark of 3M Co. for a mixture of potassium perfluoroalkyl sulfonates

In the case of albuterol, the rate of particle settling after flocculation tended to increase with surfactant concentration.

The following are examples of stable micronized drug suspension formulations according to the invention.

#### Example 18

Chilled propellant 134 a (18g) was added to perfluorodecanoic acid (25mg) in a glass aerosol vial. Micronised Beclomethasone dipropionate (50mg) was added and a metering valve crimped into place. The process was performed in a dry box.

#### Example 19

Chilled propellant 134a (18g) was added to perfluorodecanoic acid (50mg) in a glass aerosol vial. Micronised Beclomethasone dipropionate (50mg) was added and a metering valve crimped into place. The process was performed in a dry box.

#### Example 20

Chilled propellant 134a (18g) was added to perfluorodecanoic acid (1mg) in a glass aerosol vial. Micronised Albuterol sulphate (32mg) was added and a metering valve crimped into place. The process was performed in a dry box.

Example 21

Micronised fluticasone propionate (50mg) and perfluorodecanoic acid (20mg) were weighed into a glass aerosol vial. A metering valve was crimped onto the vial and propellant 134a (18g) added to the vial through the valve.

Example 22

Micronised fluticasone propionate (50mg) and perfluorodecanoic acid (50mg) were weighed into a glass aerosol vial. A metering valve was crimped onto the vial and propellant 134a (18g) added to the vial through the valve.

Claims

1. An aerosol inhalation drug formulation comprising a micronised inhalation drug, 1,1,1,2-tetrafluoroethane, and a surface active agent soluble in 1,1,1,2-tetrafluoroethane.
2. An aerosol inhalation drug formulation as claimed in Claim 1 substantially free of an adjuvant having a higher polarity than 1,1,1,2-tetrafluoroethane.
3. An aerosol inhalation drug formulation consisting of a micronised drug, 1,1,1,2-tetrafluoroethane and a surface active agent soluble in 1,1,1,2-tetrafluoroethane.
4. A formulation as claimed in any one of Claims 1 to 3 wherein the ratio of said surfactant to said drug is from about 1:100 to about 1:0.5 by weight.
5. A formulation as claimed in any one of Claims 1 to 4 wherein the ratio of said drug to propellant 134a is from about 1:100 to about 1:4000 by weight.
6. A formulation as claimed in any one of Claims 1 to 5 wherein said surfactant is a perfluorinated surfactant.
7. A formulation as claimed in Claim 6 wherein said surfactant is a perfluoroalkanoic acid of greater than 4 carbons but not greater than 20 carbons.
8. A formulation as claimed in Claim 7 wherein said perfluoroalkanoic acid is perfluorooctanoic acid or perfluorodecanoic acid.

-13-

9. A formulation as claimed in any one of Claims 1 to 8 wherein the inhalation drug is a  $\beta_2$ -stimulant, an anticholinergic drug, a corticosteroid or an anti-allergic drug.
10. A formulation as claimed in any one of Claims 1 to 8 wherein said inhalation drug is salbutamol or a pharmaceutically acceptable salt thereof.
11. A formulation as claimed in any one of Claims 1 to 9 wherein said inhalation drug is salmeterol or a pharmaceutically acceptable salt thereof.
12. A formulation as claimed in any one of Claims 1 to 8 wherein the inhalation drug is selected from fenoterol, pirbuterol, reproterol, imiterol, terbutalline, tulobuterol, isoprenaline, oxiprenaline, budesonide, fluticasone propionate, becomethasone dipropionate, ipratropium bromide, oxitropium bromide, sodium cromoglycate, ketotifen medrocromil sodium and (-)-4-amino-3,5-dichloro- $\alpha$ -[[[6-[2-(2-pyridinyl)ethoxy]hexyl]amino]methyl] benzenemethanol.
13. A formulation as claimed in any one of Claims 1 to 12 wherein said surfactant is FC-95, FC-143 or a combination thereof.
14. A formulation as claimed in any one of Claims 1 to 13 wherein said surfactant is perfluorooctanoic acid, perfluorodecanoic acid or a combination thereof and the ratio of surfactant to drug is from about 1:40 to about 1:0.5 by weight and the ratio of drug to propellant 134a is from about 1:100 to about 1:4000 by weight.
15. A formulation as claimed in any one of Claims 1 to 14 wherein said surfactant is FC-95, FC-143 or a combination thereof and the ratio of surfactant to drug is from about 1:40 to about 1:0.5 by weight and the ratio of drug to propellant 134a is from about 1:100 to about 1:4000 by weight.




17. An aerosol inhalation drug formulation comprising a micronized drug selected from the group salbutamol, salmeterol and amiloride or a pharmaceutically acceptable salt thereof, a propellant 134a-soluble surfactant in suspension in propellant 134a wherein the ratio of said surfactant to said drug is from about 1:100 to about 1:05 by weight and the ratio of drug to propellant 134a is from about 1:100 to about 1:4000 by weight and optionally other excipients

17. A formulation as claimed in Claim 16 wherein said propellant 134a-soluble surfactant is perfluorooctanoic acid, perfluorodecanoic acid FC-143 or FC-95.

# INTERNATIONAL SEARCH REPORT

International Application No **PCT/US91/04715**

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>3</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): <b>A61L 9/04</b> U.S. CL. <b>424/45</b>		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>4</sup>		
Classification System	Classification Symbols	
U.S.	424/44, 45, 46, 47	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>4</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <sup>14</sup>		
Category <sup>6</sup>	Citation of Document, <sup>16</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No. <sup>14</sup>
X Y	EP, A, 0 372 777 (RIKER LABORATORIES, INC.) 13 JUNE 1990; See entire document.	1-4 16 & 17
Y	Pharmaceutical Technology, Vol 26, MARCH 1990 "CFC Propellant Substitution: P-134a as a Potential Replacement for P-12 in MDIs", DALBY ET. AL. See entire document.	1-4 and 16-17
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>15</sup> * Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search <sup>1</sup>	Date of Mailing of this International Search Report <sup>1</sup>	
12 AUGUST 1991	01 OCT 1991	
International Searching Authority <sup>1</sup>	Signature of Authorized Officer <sup>10</sup>	
ISA/US	 Louis A. Piccone	